Eli Lilly and Novo Nordisk Lead Pharma Surge

Eli Lilly and Novo Nordisk's Weight-Loss Drugs Drive Soaring Shares

U.S.-based Eli Lilly and Denmark's Novo Nordisk are reaping the rewards of their weight-loss drugs, leading to a surge in their share prices that rivals high-growth tech stocks. Both retail and institutional investors have been flocking to these pharmaceutical giants over the past year, anticipating the explosive demand for their obesity drugs, known as GLP-1 agonists, in a market that analysts predict could exceed $100 billion.